Press Releases

Innovation and science concept

American Academy of Ophthalmology Leads Global Initiative to Address Worldwide Myopia Epidemic

The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia, where 80 to 90 percent of children and young adults are myopic.

Read More

First Patient Completes Three Year Enrollment in Nevakar’s Phase III CHAMP Study of NVK-002 Evaluating Low-Dose Atropine Ophthalmic Solution for the Treatment of Myopia in Children

Nevakar Inc., a biopharmaceutical company developing multiple products in the ophthalmic and injectable areas, announced today that the first patient has completed three year enrollment in its Phase III CHAMP…

Read More

Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials

Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection…

Read More

Nevakar and Zhaoke Ophthalmology enter into licensing agreement for NVK-002 (Atropine for the treatment of the progression of myopia in children)

Bridgewater, NJ (USA) and Hong Kong S.A.R., October 20, 2020 – Nevakar Inc. (“Nevakar”), a privately held, late-stage, biopharmaceutical company developing multiple innovative medications in the ophthalmic and hospital injectable areas, and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. (“ZKO”) announced today that they have recently entered into an exclusive licensing agreement

Read More

MyMyopia™ Introduces lnfographic for Easy Understanding of Myopia, its Impact, and Treatment Options

Bridgewater, NJ, MAY 5, 2020 – MyMyopia™ is a disease awareness effort that shares important information with parents and eye care professionals on the growing childhood myopia epidemic. It seeks to improve lifelong ocular health through education and has released an important new myopia infographic.

Read More

Nevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products

Bridgewater, NJ, OCTOBER 7, 2019 – Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has entered into a $17.5 million product financing agreement with an affiliate of H.I.G. Capital Partners, L.P. for the continued development of five differentiated, sterile injectable products.

Read More

Nevakar Completes Enrollment for its Phase III CHAMP Study of NVK-002

Bridgewater, NJ, SEPTEMBER 11, 2019 – Nevakar Inc., a privately-held, late-stage specialty pharmaceutical company dedicated to developing innovative ophthalmic products, announced today that it has completed enrollment for its Phase III CHAMP (Childhood Atropine for Myopia Progression) study, evaluating the ability of NVK-002 to slow the progression of myopia in children. NVK-002 is a unique, proprietary, preservative-free, topical investigational therapy for patients aged 3 to 17 years.

Read More

Nevakar Enters $50 Million Product Financing Agreement with NovaQuest Capital for Continued Development of Injectable Products

Bridgewater, NJ, / Raleigh, NC, JUNE 18, 2019 – Nevakar Inc. (“Nevakar” or the “Company”), a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into a $50 million product financing agreement (the “Agreement”) with an affiliate of NovaQuest Capital Management, L.L.C. for the continued development of five differentiated, sterile injectable products.

Read More

Nevakar Completes $30 Million Financing to Advance Pipeline Products

Bridgewater, NJ, NOVEMBER 29, 2018 – Nevakar Inc., a specialty pharmaceutical company developing multiple differentiated products in the ophthalmic and injectable areas, announced today that it has entered into a $20 million senior secured term loan with Oxford Finance LLC. As part of the financing agreement, Nevakar may also access an additional $10 million of funding provided that certain pre-defined milestone events are achieved. Proceeds from the financings will be used to accelerate the Company’s pipeline projects and for general corporate services.

Read More

Nevakar and Endo Enter into Exclusive Licensing Agreement for Multiple 505(b)(2) Injectable Products

Bridgewater, NJ, AUGUST 8, 2018 – Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into an exclusive licensing agreement with Endo International plc’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the U.S. and Canada.

Read More